• Molecular NameEbastine
  • SynonymNA
  • Weight469.669
  • Drugbank_IDN/A
  • ACS_NO90729-43-4
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)7.52
  • pka10.32
  • LogD (pH=7, predicted)6.24
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-5.29
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors0
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds10
  • TPSA29.54
  • StatusN/A
  • AdministrationN/A
  • PharmacologyA non-sedating H1 antihistamine.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding98.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (CYP3A4-mediated), to carebastine. Ebastine is extensively metabolised in the liver into the active metabolite, carebastine, a carboxylic acid metabolite. As metabolism is extensive, there is little parent drug present in plasma.
  • Half life13~16 h
  • ExcretionEbastine is excreted mainly in urine with 40% of a dose being recovered over a 24-h period. Approx. 6% can be detected in faeces.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A